1. A pharmaceutical composition comprising as active ingredient a drug which inhibits GST-π, and a drug that inhibits autofagiyu.2. A pharmaceutical composition according to Claim. 1, in which the active ingredient is selected from the group consisting of an RNAi molecule, a ribozyme, an antisense nucleic acid, a DNA / RNA chimeric polynucleotide and vector expressing vysheperechislennoe.3. A pharmaceutical composition according to Claim. 1 or 2, which is intended to induce apoptoza.4. A pharmaceutical composition according to claim. 3, wherein the apoptosis is induced in a cell having a mutated KRAS.5. A pharmaceutical composition according to Claim. 1 or 2 for the treatment of diseases caused by abnormal cell proliferatsiey.6. A pharmaceutical composition according to Claim. 1 or 2 for the treatment of a disease caused by a mutation KRAS.7. A pharmaceutical composition according to Claim. 1 or 2 for the treatment raka.8. A pharmaceutical composition according to claim. 7, where the cancer is caused by a mutation KRAS.9. A pharmaceutical composition for inducing apoptosis in a cell in which GST-π depressed, containing as active ingredient a drug which inhibits autofagiyu.10. A pharmaceutical composition according to claim. 9, wherein the cell has a mutated KRAS.11. A method for treating a disease selected from the group consisting of: (i) a disease caused by abnormal cell proliferation, (ii) a disease caused by mutation KRAS (iii) cancer, wherein the method comprises administering to the subject a drug that inhibits GST-π, and a medicament which inhibits autophagy.1. Фармацевтическая композиция, содержащая в качестве активных ингредиентов лекарственное средство, которое подавляет GST-π, и лекарственное средство, которое подавляет аутофагию.2. Фармацевтическая композиция по п. 1, в которой активный ингредиент выбирается из группы, состоящей из молекулы RNAi, рибозима, антисмысловой нуклеиновой кислоты, ДНК/РНК химерного полинуклеотида и вектора, экспрессирующего выш
